M. Sam Salek
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
M. Sam Salek has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
- Andrew Yule Finlay
Division of Infection and Immunity, School of Medicine, Cardiff University, Cardiff, UK
3 shared publications - P. Kamudoni
Institute of Medicines Development, Duffryn House, Cardiff, CF, 23 6NP, UK.
3 shared publications B. Mueller
Riemser Pharma GmbH, Greifswald - Insel Riems, Germany
2 shared publicationsM.K.A. Basra
Department of Dermatology and Wound Healing, School of Medicine , Cardiff University, Redwood Building, King Edward VII Avenue, Cardiff, CF10 3NB, U.K.
2 shared publicationsStuart Walker
Welsh School of Pharmacy, Cardiff University, Cardiff, UK
2 shared publicationsA. Al‐Motarreb
Al Thawrah Teaching Hospital, Sana'a, Yemen
1 shared publication
Latest Publications
- Open Access
- 1 November 2014
- Published by Springer Nature in Quality of Life Research
- Vol. 24 (4) , 1017-1027
The development and validation of a disease-specific quality of life measure in hyperhidrosis: the Hyperhidrosis Quality of Life Index (HidroQOL©)
To develop and validate a new disease-specific quality of life measure in hyperhidrosis for use in both routine clinical practice and clinical research. Interviews and focus group discussions with hyperhidrosis patients, reported elsewhere, provided the content for the measure validated in this study (n = 71). A panel of dermatologists (n = 5) and patients (n = 7) carried out content validation. Further, item reduction and the initial construct validation were carried out in a cross-sectional study (n = 595), using the unidimensional Rasch analysis and exploratory factor analysis. Subsequently, the construct validity, reliability and responsiveness of the revised measure were assessed in a longitudinal study (n = 260). Data collection for the item reduction and the final validation phases was entirely carried out online. The expert panels judged the HidroQoL as content valid. Rasch analysis supported the revision of response options from five to three. Following removal of misfitting items, a set of 15 items showed optimal fit to the model (chi-squared statistic = 159.64, p = 0.07). Three additional items were retained on consideration of their importance to patients, resulting in an 18-item instrument. The items were grouped into two subscales, daily life activities and psychosocial life domains, based on results of the factor analysis. In subsequent construct validation, the HidroQoL correlated with the DLQI (r s = 0.6, p < 0.01). Reliability was high (internal consistency, Cronbach’s alpha: overall scale = 0.9; test–retest reliability, Intra-class correlation = 0.9). The HidroQoL scores were sensitive to change in patients’ disease severity (score change from baseline to follow-up after 15–35 days, Cohen’s ES = 0.47). This study has provided the initial evidence supporting measurement properties and the use of the HidroQoL instrument in both routine clinical practice and in research, for assessing quality of life impacts in hyperhidrosis.
- 1 November 2014
- Published by Springer Nature in Quality of Life Research
- Vol. 24 (4) , 1017-1027
Open AccessThe development and validation of a disease-specific quality of life measure in hyperhidrosis: the Hyperhidrosis Quality of Life Index (HidroQOL©)
To develop and validate a new disease-specific quality of life measure in hyperhidrosis for use in both routine clinical practice and clinical research. Interviews and focus group discussions with hyperhidrosis patients, reported elsewhere, provided the content for the measure validated in this study (n = 71). A panel of dermatologists (n = 5) and patients (n = 7) carried out content validation. Further, item reduction and the initial construct validation were carried out in a cross-sectional study (n = 595), using the unidimensional Rasch analysis and exploratory factor analysis. Subsequently, the construct validity, reliability and responsiveness of the revised measure were assessed in a longitudinal study (n = 260). Data collection for the item reduction and the final validation phases was entirely carried out online. The expert panels judged the HidroQoL as content valid. Rasch analysis supported the revision of response options from five to three. Following removal of misfitting items, a set of 15 items showed optimal fit to the model (chi-squared statistic = 159.64, p = 0.07). Three additional items were retained on consideration of their importance to patients, resulting in an 18-item instrument. The items were grouped into two subscales, daily life activities and psychosocial life domains, based on results of the factor analysis. In subsequent construct validation, the HidroQoL correlated with the DLQI (r s = 0.6, p < 0.01). Reliability was high (internal consistency, Cronbach’s alpha: overall scale = 0.9; test–retest reliability, Intra-class correlation = 0.9). The HidroQoL scores were sensitive to change in patients’ disease severity (score change from baseline to follow-up after 15–35 days, Cohen’s ES = 0.47). This study has provided the initial evidence supporting measurement properties and the use of the HidroQoL instrument in both routine clinical practice and in research, for assessing quality of life impacts in hyperhidrosis.
- 1 November 2014
- Published by Elsevier in Value in Health
- Vol. 17 (7) , A611
The Burden Of Primary Hyperhidrosis On The Patient: Eq-5d-5l Utilities, Willingness To Pay And Daily Time Spent In Managing The Condition
- 1 November 2014
- Published by Elsevier in Value in Health
- Vol. 17 (7) , A611
The Burden Of Primary Hyperhidrosis On The Patient: Eq-5d-5l Utilities, Willingness To Pay And Daily Time Spent In Managing The Condition
- 10 October 2013
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 169 (4) , 760-768
Infants' Dermatitis Quality of Life Index: a decade of experience of validation and clinical application
The Infants' Dermatitis Quality of Life Index (IDQoL) is a questionnaire completed by parents to assess the impact of atopic dermatitis on the quality of life of infants aged 0-3 years. The aim was to review all clinical and psychometric data on the use of the IDQoL from its inception in 2001 until November 2012, to serve as a single reference source. A literature search was carried out using Medline, PubMed, EBSCOhost, Science Direct and Google Scholar. Articles and abstracts that described the clinical use of the IDQoL and those that investigated its psychometric properties were included. Articles not in English were excluded. Fifty-one publications were identified, of which 46 fulfilled the inclusion criteria. IDQoL data relating to psychometric, descriptive and clinical practice research, drug trials and therapeutic interventions were extracted. The IDQoL has been translated into 21 languages and used in 18 countries, including two multinational studies. Thirty-one studies demonstrated its psychometric properties, such as test-retest reliability, internal consistency, validity, responsiveness to change and interpretability. No studies investigated dimensionality, carried out factor analysis or described the minimal clinically important difference of the tool. Eight studies used the IDQoL to assess the effectiveness of therapeutic interventions such as education programmes, consultations and wet-wrap therapy, while seven studies described the use of IDQoL in topical interventions. When deciding whether to use the IDQoL, researchers and clinicians should consider the validation data, the relevant comparative clinical data available and the potential burden on the respondents.
- 10 October 2013
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 169 (4) , 760-768
Infants' Dermatitis Quality of Life Index: a decade of experience of validation and clinical application
The Infants' Dermatitis Quality of Life Index (IDQoL) is a questionnaire completed by parents to assess the impact of atopic dermatitis on the quality of life of infants aged 0-3 years. The aim was to review all clinical and psychometric data on the use of the IDQoL from its inception in 2001 until November 2012, to serve as a single reference source. A literature search was carried out using Medline, PubMed, EBSCOhost, Science Direct and Google Scholar. Articles and abstracts that described the clinical use of the IDQoL and those that investigated its psychometric properties were included. Articles not in English were excluded. Fifty-one publications were identified, of which 46 fulfilled the inclusion criteria. IDQoL data relating to psychometric, descriptive and clinical practice research, drug trials and therapeutic interventions were extracted. The IDQoL has been translated into 21 languages and used in 18 countries, including two multinational studies. Thirty-one studies demonstrated its psychometric properties, such as test-retest reliability, internal consistency, validity, responsiveness to change and interpretability. No studies investigated dimensionality, carried out factor analysis or described the minimal clinically important difference of the tool. Eight studies used the IDQoL to assess the effectiveness of therapeutic interventions such as education programmes, consultations and wet-wrap therapy, while seven studies described the use of IDQoL in topical interventions. When deciding whether to use the IDQoL, researchers and clinicians should consider the validation data, the relevant comparative clinical data available and the potential burden on the respondents.
- 1 June 2013
- Vol. 148 (3) , 263-75
Quality of life measurement in dermatology consultation: impact on patient reported outcomes.
It is now recognized that therapy should not only seek to cure disease, but also to affect outcomes that matter to the patients the most; those related to their functioning in their everyday life and their overall quality of life. In those situations where elimination of disease/complete cure is not possible for example in chronic conditions, limiting the complications from the illness, so that patients can still maintain a comfortable and satisfying life, becomes the goal of treatment. This coupled with the growing patient rights movement and the need for patients to be a part of treatment decision-making process means that patient's health-related quality of life is no longer just an important consequence of health-care, but it is increasingly regarded as an explicit ultimate goal.
- 1 June 2013
- Vol. 148 (3) , 263-75
Quality of life measurement in dermatology consultation: impact on patient reported outcomes.
It is now recognized that therapy should not only seek to cure disease, but also to affect outcomes that matter to the patients the most; those related to their functioning in their everyday life and their overall quality of life. In those situations where elimination of disease/complete cure is not possible for example in chronic conditions, limiting the complications from the illness, so that patients can still maintain a comfortable and satisfying life, becomes the goal of treatment. This coupled with the growing patient rights movement and the need for patients to be a part of treatment decision-making process means that patient's health-related quality of life is no longer just an important consequence of health-care, but it is increasingly regarded as an explicit ultimate goal.
- Open Access
- 1 January 2013
- Published by Springer Nature in Health and Quality of Life Outcomes
- Vol. 11 (1) , 78
The development and validation of the major life changing decision profile (MLCDP)
Chronic diseases may influence patients taking major life changing decisions (MLCDs) concerning for example education, career, relationships, having children and retirement. A validated measure is needed to evaluate the impact of chronic diseases on MLCDs, improving assessment of their life-long burden. The aims of this study were to develop a validated questionnaire, the “Major Life Changing Decision Profile” (MLCDP) and to evaluate its psychometric properties. 50 interviews with dermatology patients and 258 questionnaires, completed by cardiology, rheumatology, nephrology, diabetes and respiratory disorder patients, were analysed for qualitative data using Nvivo8 software. Content validation was carried out by a panel of experts. The first version of the MLCDP was completed by 210 patients and an iterative process of multiple Exploratory Factor Analyses and item prevalence was used to guide item reduction. Face validity and practicability was assessed by patients. 48 MLCDs were selected from analysis of the transcripts and questionnaires for the first version of the MLCDP, and reduced to 45 by combination of similar themes. There was a high intraclass correlation coefficient (0.7) between the 13 members of the content validation panel. Four more items were deleted leaving a 41-item MLCDP that was completed by 210 patients. The most frequently recorded MLCDs were decisions to change eating habits (71.4%), to change smoking/drinking alcohol habits (58.5%) and not to travel or go for holidays abroad (50.9%). Factor analysis suggested item number reduction from 41 to 34, to 29, then 23 items. However after taking into account item prevalence data as well as factor analysis results, 32 items were retained. The 32-item MLCDP has five domains education (3 items), job/career (9), family/relationships (5), social (10) and physical (5). The MLCDP score is expressed as the absolute number of decisions that have been affected. The 32-item (5 domains) MLCDP has been developed as an easy to complete generic tool for use in clinical practice and for quality of life and epidemiological research. Further validation is required.
- 1 January 2013
- Published by Springer Nature in Health and Quality of Life Outcomes
- Vol. 11 (1) , 78
Open AccessThe development and validation of the major life changing decision profile (MLCDP)
Chronic diseases may influence patients taking major life changing decisions (MLCDs) concerning for example education, career, relationships, having children and retirement. A validated measure is needed to evaluate the impact of chronic diseases on MLCDs, improving assessment of their life-long burden. The aims of this study were to develop a validated questionnaire, the “Major Life Changing Decision Profile” (MLCDP) and to evaluate its psychometric properties. 50 interviews with dermatology patients and 258 questionnaires, completed by cardiology, rheumatology, nephrology, diabetes and respiratory disorder patients, were analysed for qualitative data using Nvivo8 software. Content validation was carried out by a panel of experts. The first version of the MLCDP was completed by 210 patients and an iterative process of multiple Exploratory Factor Analyses and item prevalence was used to guide item reduction. Face validity and practicability was assessed by patients. 48 MLCDs were selected from analysis of the transcripts and questionnaires for the first version of the MLCDP, and reduced to 45 by combination of similar themes. There was a high intraclass correlation coefficient (0.7) between the 13 members of the content validation panel. Four more items were deleted leaving a 41-item MLCDP that was completed by 210 patients. The most frequently recorded MLCDs were decisions to change eating habits (71.4%), to change smoking/drinking alcohol habits (58.5%) and not to travel or go for holidays abroad (50.9%). Factor analysis suggested item number reduction from 41 to 34, to 29, then 23 items. However after taking into account item prevalence data as well as factor analysis results, 32 items were retained. The 32-item MLCDP has five domains education (3 items), job/career (9), family/relationships (5), social (10) and physical (5). The MLCDP score is expressed as the absolute number of decisions that have been affected. The 32-item (5 domains) MLCDP has been developed as an easy to complete generic tool for use in clinical practice and for quality of life and epidemiological research. Further validation is required.
- Open Access
- 1 January 2013
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 4, 66
Burden of Friedreich’s Ataxia to the Patients and Healthcare Systems in the United States and Canada
Objective: The study intended to substantiate healthcare resource utilization, costs, and funding patterns of US and Canadian Friedreich’s Ataxia (FRDA) populations, to assess compliance with treatment guidance and to identify areas where novel healthcare measures or improved access to existing care may improve patients’ functional and social capabilities and reduce the financial impact on the healthcare systems. Methods: Healthcare resource utilization and costs were collected in a cross-sectional study in the US (N = 197) and Canada (N = 43) and analyzed across severity of disease categories. Descriptive statistics, correlation analysis, and hypothesis testing were applied. Results: In the US, healthcare costs of FRDA patients were higher than those of “adults with two and more chronic conditions.” Significantly higher costs were incurred in advanced stages of the disease, with paid homecare being the main driver. This pattern was also observed in Canada. Compliance with the recommended annual neurological and cardiological follow-up was high, but was low for the recommended regular speech therapy. In the US public and private funding ratios were similar for the FRDA and the general populations. In Canada the private funding ratio for FRDA was higher than average. Conclusion: The variety of healthcare measures addressing the broad range of symptoms of FRDA, and the increasing use of paid home care as disease progresses made total US healthcare costs of FRDA exceed the costs of US adults with two and more chronic conditions. Therefore, measures delaying disease progression will allow patients to maintain their independence longer and may reduce costs to the healthcare system. Novel measures to address dysarthria and to ensure access to them should be further investigated. The higher than average private funding ratio in Canada was due to the relatively high cost of the pharmacological treatment of FRDA.
- 1 January 2013
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 4, 66
Open AccessBurden of Friedreich’s Ataxia to the Patients and Healthcare Systems in the United States and Canada
Objective: The study intended to substantiate healthcare resource utilization, costs, and funding patterns of US and Canadian Friedreich’s Ataxia (FRDA) populations, to assess compliance with treatment guidance and to identify areas where novel healthcare measures or improved access to existing care may improve patients’ functional and social capabilities and reduce the financial impact on the healthcare systems. Methods: Healthcare resource utilization and costs were collected in a cross-sectional study in the US (N = 197) and Canada (N = 43) and analyzed across severity of disease categories. Descriptive statistics, correlation analysis, and hypothesis testing were applied. Results: In the US, healthcare costs of FRDA patients were higher than those of “adults with two and more chronic conditions.” Significantly higher costs were incurred in advanced stages of the disease, with paid homecare being the main driver. This pattern was also observed in Canada. Compliance with the recommended annual neurological and cardiological follow-up was high, but was low for the recommended regular speech therapy. In the US public and private funding ratios were similar for the FRDA and the general populations. In Canada the private funding ratio for FRDA was higher than average. Conclusion: The variety of healthcare measures addressing the broad range of symptoms of FRDA, and the increasing use of paid home care as disease progresses made total US healthcare costs of FRDA exceed the costs of US adults with two and more chronic conditions. Therefore, measures delaying disease progression will allow patients to maintain their independence longer and may reduce costs to the healthcare system. Novel measures to address dysarthria and to ensure access to them should be further investigated. The higher than average private funding ratio in Canada was due to the relatively high cost of the pharmacological treatment of FRDA.
- 25 August 2012
- Published by S. Karger AG in Dermatology
- Vol. 225 (1) , 45-53
The Role of the EQ-5D in the Economic Evaluation of Dermatological Conditions and Therapies
Economic evaluation is an increasingly important aspect of assessment of the burden of skin diseases. Although dermatology data were not used in its development, the use of the EQ-5D questionnaire has been encouraged by the requirement of health technology assessment agencies for utility comparisons informing reimbursement decisions. The aim of this review was to examine the use of the EQ-5D in dermatology and to consider its future role in the economic evaluation of skin diseases. Published studies reporting the use of the EQ-5D in the economic analysis of skin diseases were carefully examined. Nineteen articles and 1 abstract published between 2003 and 2011 were identified, in which cost-of-illness, cost-effectiveness and cost-utility analyses were described. The EQ-5D is not a dermatology-specific measure, and it is not yet clear whether it is the most appropriate measure to support economic evaluation in the context of dermatology.
- 25 August 2012
- Published by S. Karger AG in Dermatology
- Vol. 225 (1) , 45-53
The Role of the EQ-5D in the Economic Evaluation of Dermatological Conditions and Therapies
Economic evaluation is an increasingly important aspect of assessment of the burden of skin diseases. Although dermatology data were not used in its development, the use of the EQ-5D questionnaire has been encouraged by the requirement of health technology assessment agencies for utility comparisons informing reimbursement decisions. The aim of this review was to examine the use of the EQ-5D in dermatology and to consider its future role in the economic evaluation of skin diseases. Published studies reporting the use of the EQ-5D in the economic analysis of skin diseases were carefully examined. Nineteen articles and 1 abstract published between 2003 and 2011 were identified, in which cost-of-illness, cost-effectiveness and cost-utility analyses were described. The EQ-5D is not a dermatology-specific measure, and it is not yet clear whether it is the most appropriate measure to support economic evaluation in the context of dermatology.
- Open Access
- 1 January 2012
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 3, 38
Do Patient-Reported Outcomes Have a Role in the Management of Patients with Cystic Fibrosis?
Background: Health-related quality of life (HRQoL) is a rapidly growing area of expertise and the most commonly used patient-reported outcome (PRO). The impact of cystic fibrosis (CF) on HRQoL is liable to be great, making CF patients ideal candidates for the application of HRQoL instruments. The aims of this study were to assess the affect of CF on HRQoL, to ascertain the reliability and validity of the United Kingdom Sickness Impact Profile (UKSIP) and the Cystic Fibrosis Quality of Life Questionnaire (CFQoL) in the adult CF population, and to examine their role in the management of patients. Methods: Seventy participants were recruited from the All Wales Adult Cystic Fibrosis Centre at Llandough Hospital, UK. There were two stages to the study: self-report of the UKSIP and CFQoL; and completion of the same two questionnaires 7–10 days later. Results: The areas of HRQoL most impaired by CF were employment and concerns regarding the future. The UKSIP and CFQoL showed high internal consistency (rα = 0.89–0.93) and test–retest reliability (rs = 0.57–0.94, p < 0.005) in the CF population. Validity was variable with the UKSIP showing discrimination across socio-demographic factors, whilst the CFQoL showed increased sensitivity to clinical variables. Many parameters influenced patient-reported HRQoL, with the greatest correlations seen with the Borg score (p < 0.005). The use of a HRQoL instrument in CF annual reviews is recommended to provide holistic patient care. The results of this study underpin the value of HRQoL as a patient-reported outcome measure in the management of adult CF.
- 1 January 2012
- Published by Frontiers Media SA in Frontiers in Pharmacology
- Vol. 3, 38
Open AccessDo Patient-Reported Outcomes Have a Role in the Management of Patients with Cystic Fibrosis?
Background: Health-related quality of life (HRQoL) is a rapidly growing area of expertise and the most commonly used patient-reported outcome (PRO). The impact of cystic fibrosis (CF) on HRQoL is liable to be great, making CF patients ideal candidates for the application of HRQoL instruments. The aims of this study were to assess the affect of CF on HRQoL, to ascertain the reliability and validity of the United Kingdom Sickness Impact Profile (UKSIP) and the Cystic Fibrosis Quality of Life Questionnaire (CFQoL) in the adult CF population, and to examine their role in the management of patients. Methods: Seventy participants were recruited from the All Wales Adult Cystic Fibrosis Centre at Llandough Hospital, UK. There were two stages to the study: self-report of the UKSIP and CFQoL; and completion of the same two questionnaires 7–10 days later. Results: The areas of HRQoL most impaired by CF were employment and concerns regarding the future. The UKSIP and CFQoL showed high internal consistency (rα = 0.89–0.93) and test–retest reliability (rs = 0.57–0.94, p < 0.005) in the CF population. Validity was variable with the UKSIP showing discrimination across socio-demographic factors, whilst the CFQoL showed increased sensitivity to clinical variables. Many parameters influenced patient-reported HRQoL, with the greatest correlations seen with the Borg score (p < 0.005). The use of a HRQoL instrument in CF annual reviews is recommended to provide holistic patient care. The results of this study underpin the value of HRQoL as a patient-reported outcome measure in the management of adult CF.
- 1 January 2012
- Published by Springer Nature in Drug Information Journal
- Vol. 46 (1) , 73-83
Development and Application of Scorecards to Assess the Quality of a Regulatory Submission and Its Review
- 1 January 2012
- Published by Springer Nature in Drug Information Journal
- Vol. 46 (1) , 73-83
Development and Application of Scorecards to Assess the Quality of a Regulatory Submission and Its Review
- 1 January 2012
- Published by Springer Nature in Drug Information Journal
- Vol. 46 (1) , 57-64
An Appraisal of Good Regulatory Review Practices in the Gulf Cooperation Council States
- 1 January 2012
- Published by Springer Nature in Drug Information Journal
- Vol. 46 (1) , 57-64
An Appraisal of Good Regulatory Review Practices in the Gulf Cooperation Council States